Inhaled corticosteroids do not reduce initial high activity of matrix metalloproteinase (MMP)-9 in exhaled breath condensates of children with asthma exacerbation: a proof of concept study
| Autor: | Katarzyna Grzela, Alicja Krejner, Aleksandra Banaszkiewicz, Malgorzata Litwiniuk, Marek Kulus, Tomasz Grzela, Wioletta Zagórska |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
exhaled breath condensate
Pathology medicine.medical_specialty Exacerbation Short Communication Immunology Inflammation Matrix metalloproteinase asthma exacerbation 03 medical and health sciences 0302 clinical medicine medicine Immunology and Allergy Exhaled breath condensate Asthma business.industry medicine.disease respiratory tract diseases 030228 respiratory system Exhaled nitric oxide Tumor necrosis factor alpha inhaled corticosteroids medicine.symptom MMP-9 business Airway 030215 immunology |
| Zdroj: | Central-European Journal of Immunology |
| ISSN: | 1426-3912 |
| DOI: | 10.5114/ceji.2016.60998 |
| Popis: | Inhaled corticosteroids (ICS) are the key component of asthma treatment. However, it is unclear whether they could control the activity and level of matrix metalloproteinase (MMP)-9, which is an important factor in asthma-associated inflammation and airway remodeling. Therefore, the aim of this proof of concept study was to analyze the influence of increased doses of ICS on MMP-9 in exhaled breath condensates (EBC) of patients with allergic asthma exacerbation. Apart from MMP-9, the assessment concerned selected inflammation markers – exhaled nitric oxide (eNO) and cytokines (IL-8 and TNF). The study involved a small group (n = 4) of individuals with asthma exacerbation. The intervention concerned increased doses of ICS with β-mimetics for 4 weeks. In addition to clinical evaluation, eNO measurements and EBC collections were done before and after 4 weeks of intense ICS treatment. The biochemical assessment of EBC concerned MMP-9, IL-8 and TNF. The data were compared to results of healthy controls (n = 6). The initial levels of eNO, MMP-9 and TNF in EBC were higher in the asthma group than in controls. In all subjects IL-8 levels were below the detection limit. After 4 weeks of ICS treatment in all patients we observed improvement of clinical and laboratory parameters. Interestingly, despite reduction of eNO and TNF, the activity of MMP-9/EBC remained on the initial level. Practical relevance of our results is limited by a small group. Nevertheless, our data suggest that ICS, although sufficient to control symptoms and inflammatory markers, may be ineffective to reduce MMP-9/EBC activity in asthma exacerbation and, possibly, airway remodeling. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|